Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
Seagen Inc.
Eli Lilly and Company
M.D. Anderson Cancer Center
Sun Yat-sen University
GOG Foundation
M.D. Anderson Cancer Center
Genmab
Eisai Inc.
University of Colorado, Denver
Institute of Cancer Research, United Kingdom
Duke University
AbbVie
AstraZeneca
Yale University
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
GlaxoSmithKline
University of Kentucky
AstraZeneca
University of Oklahoma
Gilead Sciences
Hoffmann-La Roche
Merck Sharp & Dohme LLC
City of Hope Medical Center
Washington University School of Medicine
Rutgers, The State University of New Jersey
AstraZeneca
University of Iowa
Incyte Corporation
ARCAGY/ GINECO GROUP
NeoTX Therapeutics Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
SystImmune Inc.
University of Oklahoma
Merck Sharp & Dohme LLC
Vanderbilt-Ingram Cancer Center
Memorial Sloan Kettering Cancer Center
University of British Columbia
Exelixis
Cancer Research UK
National Cancer Institute (NCI)
GlaxoSmithKline
Danish Gynecological Cancer Group
Dana-Farber Cancer Institute
University of Alabama at Birmingham